Early-stage, high-risk/high-impact technology development to improve collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and derivatives (e.g., DNA/RNA/proteins). Part of NCI’s IMAT program. Not for hypothesis-driven studies using existing tech.
Eligibility Criteria:
-
Applicant organizations: higher-ed institutions, nonprofits, for-profits (incl. small businesses), governments, tribal entities, foreign organizations; foreign components allowed.
-
PD/PI must have an eRA Commons ID.
-
Multiple applications allowed if scientifically distinct.
-
Clinical trials are not allowed.
Funding Details:
-
Mechanism: R61 (Phase 1 exploratory/developmental).
-
Budget: up to 150,000 USD direct costs/year, up to 3 years.
Deadline:
-
Application due dates: October 3, 2025 (5:00 PM local time).
Where to Go for Further Information:
- Program details.
-
Scientific/Research: Kelly Crotty, Ph.D. — [email protected]
-
General Grants Info: [email protected]